CBD

Hear a Noid Factoid from our latest podcast guest!

When you think of cannabis, you probably don’t think of horses or the potential medicinal benefit to animals. However, the cannabinoids found in cannabis have been shown to provide similar benefits in animals that are noted with human patients. In this interview, Emma Davis, founder of Mikko’s Choice, delves into how some cannabinoids—such as tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), and tetrahydrocannabinolic acid (THCA)—have provided medicinal benefits to horses. Davis also discusses her mustang, Mikko, who inspired her to launch her own cannabis and hemp product brand.

In this article, we explore the difference in chemical profile between fresh and dry cannabis flower and why manufacturers may choose to extract frozen or dry cannabis.

Recently, the University of Oxford began an international study to examine the potential therapeutic benefits of cannabidiol (CBD) in treating psychosis or psychotic symptoms.

Cannabidiol (CBD) was recently studied in Mexico as a treatment for traumatic brain injury and Parkinson’s Disease.

There goes another year in the books. This review of 2022’s extraction greatest hits takes a look at discoveries, advancements in technology, and other highlights from the year. This article also lays out some predictions for 2023, which is set up to be an interesting year with less access to funding that could slow the development of new technology or innovation in the extraction space.

A statement released on Thursday, January 26, 2023 from Dr. Janet Woodcock, the principal deputy commissioner of the Food and Drug Administration (FDA), announced that the FDA will work with Congress in formulating regulatory oversight to balance risk and access for products in the cannabidiol (CBD) market.

Currently in the life cycle of the cannabis industry, it is not obvious where the heavy metal regulatory landscape will end up. Clearly, the big four are not enough, but what is a realistic panel that reflects the real world of cannabinoid production?

One of the recurring challenges in the medical cannabis space is the difficulty in conducting research because of the plant’s Schedule I status. Although there are some researchers diving in with special licenses to conduct clinical studies, there are others that are looking at real-world users to supply data. For instance, Dr. Daniel J. Kruger is a Research Investigator with the Population Study Center at the University of Michigan and Principal Investigator on a study being conducted with the Releaf app. Here, Dr. Kruger shares his interest and background in these types of surveys and his plans for the current study with Releaf on chronic pain.

Recently, some major food and beverage companies expressed interest in selling products containing cannabidiol (CBD), but the Food and Drug Administration (FDA) have not indicated any regulatory progress.

A review of the claims that differences in extract type can affect cost, ease of formulation, and the experience of the finished product.

This article examines why we should be studying the cannabinoids beyond THC and CBD in order to explore their potential medical value.

The various extract types are defined so there can be some consensus once and for all.

In the work presented here, the authors evaluated the effects of variable red-light exposure on the phytochemical content of four Group III cannabis cultivars.

When a patient isn’t able to access the care or medication that they need in their home country, they aren’t left with much of a choice but to travel to a country that will give them the treatment they need. In part II of this interview series, Nikki Lawley, founder of Nikki and the Plant, LLC, and retired licensed practical nurse (LPN), continues discussing her journey to health, the broken healthcare system hurting medical cannabis patients in the US, and what needs to change to make access better for patients.

Recently, Leafreport, an Israeli company that provides reviews and comparisons of cannabidiol (CBD) companies and products, released their 2022 report on their transparency analysis for 4384 CBD products.

This article investigates the chiral method development screening for the enantiomeric separation of synthetic CBD on polysaccharide-based chiral stationary phases with both normal-phase and reversed phase mobile phases, using HPLC and UHPLC.

Part II of a guided tour through the protein structure and function influence of cannabinoid receptor 2 (CB2R) on cannabinoid signaling.

Cannabidiol (CBD) has been a hot topic for several years now and it seems like you can buy CBD almost anywhere. As a consumer, how do you know that the CBD at your local drug store is the same quality at a cannabis or hemp retail store? Education is key to knowing the difference and finding a top-notch product. In this interview, Vince Sanders, founder and president of CBD American Shaman, discusses his company’s approach to cannabis retail, their main motivators for success, and his plans for continual expansion in the cannabis industry.

The new processed cannabis products continue to attract consumers—but black market influence causes hesitancy.

It is demonstrated in this paper that cell viability can be used to determine dose and response effects that are important in understanding toxicities and to detect differences in similar hemp products.

A discussion on the selection of a “golden” potency method including what this method should look like, how we should go about choosing it, and more.

THC isomers are defined and discussed to better understand where they come from, how they are produced, and how they are being distributed.

How does the pharmaceutical industry test better to avoid mislabeling problems?

Can Carbon-14 testing determine the natural content of CBD products and ingredients?